To discover and develop a new class of
pharmaceutical compounds based on the biological functions of the interactions between
glycoconjugates and their receptors.
Currently, GlycoTech is involved in a corporate alliance with Novartis,
Basel Switzerland. Our objective is to develop novel compounds to inhibit the interaction
of the selectins with their carbohydrate ligands for the treatment of disease (eg.
inflammation) or conditions (eg. reperfusion injury) caused by the recruitment of
leukocytes to affected tissues.
GlycoTech also maintains a collaborative research agreement with the
Chicago Institute for Neurosurgery and Neuroresearch to study the role of carbohydrates in
the functioning of the central nervous system. Applications from this research involve
novel therapeutic approaches for the treatment of brain tumors, Alzheimer's disease, and
Many tumor markers defined by monoclonal antibodies have been
identified as carbohydrate structures. GlycoTech has developed an extensive data base of
monoclonal antibodies directed against carbohydrates and is aggressively pursuing their
use in identifying early stages of cancer with several diagnostic companies.
GlycoTech is actively seeking other pharmaceutical partners and offers
a combined range of expertise focusing on the Glycobiology area. The corporate structure
and strategy of GlycoTech allows its partners to quickly obtain this unique expertise and
avoid the obligations encountered with the fixed financial responsiblities associated with
internal organic growth. We welcome the opportunity to meet with all interested parties to
explore mutually constructive collaborations.
FINE CHEMICALS and REAGENTS BUSINESS
The purpose of this division of GlycoTech is to make techniques and
reagents available to all scientists in order to broaden investigations of carbohydrates
into other fields of research such as Cell Biology, Immunology, Neurobiology, and
Molecular Biology. The first section of the catalog contains some useful protocols written
by well known scientists covering a wide range of topics in Glycobiology. The following
sections contain a variety of unique carbohydrate reagents that allow many of these
protocols to be followed in laboratories not necessarily specializing in Glycobiology.
This catalog also welcomes the participation of scientists within this field with the
objective to actively support their research and discoveries. GlycoTech's long-term goal
is to use our technology and reagents for research towards new discoveries of the
biological functions of carbohydrates based on the interaction of glycoconjugates and
their receptors. We hope that this catalog fulfills these goals and promotes the
application of discoveries to the biomedical community.
Copyright © 1996-99 by GlycoTech Corporation. All rights